This transcript was created using speech recognition software. While it has been reviewed by human transcribers, it may contain errors. Please review the episode audio before quoting from this transcript and email transcripts@nytimes.com with any questions.
From “New York Times,” I’m Michael Barbaro. This is “The Daily.”
Today, a new experimental vaccine could become the first of its kind to treat cancer. My colleague, health reporter Nina Agrawal, explains how a century-old idea is finally becoming a reality, and where this breakthrough could lead to next.
It’s Monday, November 16.
Nina, welcome back to “The Daily.”
Hi, Michael. Thanks for having me.
My pleasure. You come to us with some relatively big news from the world of cancer treatment, and everyone is fascinated and invested in us figuring out how to treat cancer. What are the developments?
Yeah, I do have big news. And that is that really a first of its kind vaccine to treat cancer was shown to work.
And explain why that’s such a big deal.
So scientists have tried and failed for decades, if not longer, to develop a vaccine that could be used to treat cancer. But it’s really a very challenging thing.
Why?
If you think about how vaccines work in infectious disease, we give somebody a vaccine to prevent the disease.
Flu, COVID.
Correct. RSV.
Smallpox.
And cancer is, even within a specific cancer, it’s very varied, it’s very heterogeneous. One person’s cancer is not exactly the same as the next person’s cancer. So you can’t easily vaccinate all individuals against something that’s going to be so individualized.
Cancer, by definition, is the extremely unique mutation of a cell that becomes cancerous in your body. And it sounds like you’re saying the impediment to a cancer vaccine is that you can’t immunize the human body against the possibility so far that a cell is going to go rogue.
I think here the big breakthrough is actually being able to develop a vaccine that does respond to that individual nature of cancer. So what the scientists were able to do here was treat people who already have cancer with a vaccine that is individualized to that cancer.
So very much changing the timeline of a vaccine from before someone gets sick to after they’ve already gotten cancer.
Yeah. The way we traditionally think about vaccines against infectious disease being given when somebody is healthy and has no exposure, and this is a different paradigm where you’re using it to treat cancer once somebody has already been diagnosed with it.
So let’s get into the specifics of exactly how this has worked.
So basically, what’s happened now is that scientists have created a vaccine against melanoma.
Skin cancer.
Skin cancer. So they took patients, more than 1,100 who had melanoma stage II, III, or IV.
Pretty serious cancer.
Yes. They took patients who had been diagnosed with melanoma, had it surgically removed. They basically have minimal disease left in their body, but they are at high risk for it to come back. And so they thought this was the right window to vaccinate. And what they do is when they remove the tumor, they sequence its DNA so they can identify all of the mutations, which are the errors or changes in the DNA that the tumor harbors.
So they’re really getting down to the genetically-specific elements of an individual’s cancer.
Right. And then what they’re doing is they’re trying to predict which of those mutations, because in melanoma, a cancer cell can have hundreds of mutations. They’re trying to predict which one of those our immune system can see and recognize and then attack. So basically, the way our immune system does that is these mutations produce proteins on the cell surface, which are like enemy flags to our immune system.
So our immune cells are going around the body. And when they see these unusual abnormal foreign proteins like enemy flags, they know to go and attack the cells. But for a number of reasons, when people get cancer, the immune system doesn’t do this completely. Some tumors, they are able to hide from the immune system. But the researchers said, OK, we see what are all these mutations that produce these enemy flags, which ones do we think are the most likely to be perceived as an enemy flag by the immune system? They picked, I think, up to 34.
Wow.
They’re trying to maximize their chances. And instead of putting the proteins, those enemy flags, directly into the body, they put mRNA in. mRNA is messenger RNA. It’s something we produce in our bodies naturally. It’s instructions from our DNA —
— to create proteins. I remember this from AP Biology.
So what the scientists are inserting in the body in the vaccine is this mRNA encoding up to 34 of these enemy flags.
Wow, science man.
Yes. And they’re personalized to every individual in the hopes that the immune system will see some of those enemy flags, mount a response, and attack the tumor cells.
Let me just summarize, because this is both fascinating and complicated. These scientists, they are taking a little piece of this melanoma cancer, and they are studying these proteins and then creating a vaccine that inserts instructions for the body to recreate those proteins so that our immune system will see them waving their big protein red flags, see them as enemies and attack them, and in theory, keep that cancer at bay.
You got it.
So what happens when this magical process results in a vaccine that’s inserting these mRNA instructions into these folks who have melanoma?
So in this study, the people with melanoma who got the vaccine received nine doses.
Full of vaccine?
Yeah. I think the idea is to keep boosting the immune response. And so they received one dose every three weeks. I talked to patients who received it and they might have had a sore arm or flu-like symptoms for a day or two, but basically very minimal side effects for a cancer therapy. And then the researchers followed them.
How long did they follow them for?
They have data from this trial for two years. And they were able to show that the people who received the vaccine were 42 less likely to have the cancer come back than the people who did not.
42 percent less likely to have the cancer come back. That seems like a big number. Is it?
Yeah. The experts I talked to say that’s on par with some of their biggest breakthroughs. And the researchers also found that the patients who received the vaccine were less likely not only to have the cancer come back, but they were also less likely to have it spread far in the body or become metastatic.
So if it came back, it was less likely to become the worst kind of cancer, metastatic cancer.
Right. But this is two years of data. So they don’t have overall long-term survival data. And scientists need to keep following the patients for years to see if the results hold up. But it is a big deal. So because of this success, the companies that have made this vaccine, which is Merck and Moderna, are planning to apply for FDA approval. And the big question is, will it work for other cancers? If so, which ones? Could it one day be used to prevent cancer upfront?
And beyond that, this is a big breakthrough for the idea that vaccines might work to treat cancer. And that’s something that scientists have been trying to do and failing at for more than 100 years.
We’ll be right back.
Nina, tell us the story of what sounds like 100 years of frustrating failure when it comes to a vaccine to treat cancer. And then let’s talk about whether or not what has happened with this vaccine that works reasonably well against melanoma might represent the beginning of an entirely new era in vaccinating against cancer.
So if you ask researchers who work in this field when was the start, a lot of people will point you to Dr. William Coley, a bone surgeon in the 1890s.
Wow, we’re talking really long time ago.
Yeah, more than 100 years. And he stumbled into this principle by accident. He had read about a patient who had spontaneous regression of their tumor, meaning by itself started to shrink. And it happened after the patient got infected with a bacteria and had a fever.
Because their immune system was in overdrive.
I think that’s the hypothesis. He didn’t really know that at the time. He thought, well, the bacteria has something to do with cancer. And what he did start trying to do was inject the tumors with these bacterial mixtures. And in a few of the patients, he did see tumor regression.
He was figuring something out. He probably didn’t exactly what he was figuring out.
He didn’t know, and others also didn’t know. And probably what might have been happening was the bacteria were stimulating an immune response. And because it was being injected right into the tumor, those immune cells were also acting on the tumor. But he didn’t know that at the time. And shortly thereafter, it was dismissed as quackery and forgotten. And that’s partly because other effective treatments came on the scene, which were radiation and chemotherapy, later on.
So the idea of a vaccine falls by the wayside?
Yeah, it petered out. But fast forward to the 1980s, and this idea that the immune system might be used to treat cancer is starting to pick up steam. And it’s not necessarily using a vaccine, but finding ways to turn up the immune system, send it into overdrive and realizing that that could be a fruitful treatment. This field is called immunotherapy, and the first treatment in that field was approved in, I think, 1986. And then a few key developments happened in the 1990s, the 2000s, the 2010s, that I would say really allowed us to get to where we are today.
And what are those?
So one is being able to sequence the Human Genome. I mean, that was a project that originally took many years and hundreds of millions, if not $1 billion. And now you can sequence an individual genome for hundreds of dollars.
And in just a couple of days.
Well, a couple of weeks, maybe. Yeah, it’s a much faster and cheaper process. So the ability to sequence an individual’s genome and an individual cancer genome is really key to being able to find the elements that we can put into a vaccine. So that’s one. Another is the development of a certain kind of immune therapy called immune checkpoint inhibitors. And these are basically a class of drugs that take the brakes off of the immune system. The immune system has a natural way of putting the brakes on when it’s responding to some sort of infection, or so that you don’t like, start attacking your own cells or develop some autoimmune condition.
And cancer cells hijack that process. And so they’re telling the immune system to put the brakes on when actually you want the immune system to be attacking those cells.
Fascinating.
So the cancer vaccine is given in conjunction with a drug that does this.
And in combination, you get something like that 42 percent reduction in the recurrence of melanoma for two years.
Yes. I mean, and that was a significant change in our understanding, was realizing, OK, you might produce a vaccine that elicits an immune response in a petri dish, but researchers weren’t actually seeing a clinical benefit. And one of the reasons was that the immune system was —
— inhibited.
Yes. And so being able to de-inhibit the immune system, being able to take the brakes off the immune system enabled the vaccine to work. And then there were a lot of thoughts about what the best way to give that vaccine would be. People thought maybe DNA, people thought maybe the actual proteins themselves, maybe mRNA. And none of those is easy or cheap. But with the COVID experience, scientists and Moderna, in particular, learned how to manufacture mRNA vaccines quickly and at scale. And so that really enabled scientists to figure out how to make this customizable mRNA vaccine that’s individualized to somebody’s cancer.
So the world of science needed to go through a lot, including the Human Genome Project, which, as you said, took so long. It needed the experience, as you just said, of COVID, to master rapid, scalable mRNA vaccines. It needed time and, in the case of COVID, trauma to get to this place.
Yeah, there were a lot of advancements that were building on each other over the years, and that all came to a head in the last 10 to 15 years.
This is very helpful in understanding how we get here and the scientific process. I think the question that anyone who is listening to this episode now has is, what if I have cancer or I know someone, I love someone who has cancer and it’s not melanoma, it’s one of the dozens, if not hundreds of other cancers, what does this development mean for that cancer and for those people?
I think scientists are a little bit mixed on what they would tell you, based on this trial. Some say melanoma is a pretty unique cancer. It has a lot of mutations, so it’s more easy to be seen by the immune system. What works for melanoma may not work for all the other solid tumors, breast cancer, colon cancer, pancreatic cancer. At the same time, there are trials being done in some of these other cancers. Probably the most promising one, and the one that is being most closely watched is in pancreatic cancer, where a small study of 16 patients showed that patients who received an mRNA vaccine, also again, after surgery, were less likely to have it come back within some time period.
That was an early trial, but there is a larger randomized study ongoing. And so that is one that’s really being closely watched. I think the hope certainly is that researchers can figure out a way to make this work for other cancers as well.
But I have to think that bespoke vaccines of the we’re talking about here are going to be extremely expensive to produce, because instead of a company making a vaccine that lots and lots of people can use, they’re making a vaccine that is for one person. And by definition, that means it’s not going to be super cost efficient, right?
Right. They’re making an individualized vaccine for an individual person. So any vaccine like this would be quite expensive. But in general, cancer therapies today are quite expensive running in the hundreds of thousands of dollars.
Wow. So for this to ever become a bigger solution to cancer, do doctors and scientists think that it has to move away from this bespoke solution that you’re describing with the melanoma clinical trials? Does it have to be a vaccine that doesn’t rely on sequencing just one person’s specific tumor?
So I don’t think scientists are necessarily going to move away altogether from the bespoke solution. This is a field that they’re really experimenting a lot with.
And that’s promising.
Right. And that’s showing promise. But researchers are also looking at the possibility of what they call an off-the-shelf cancer vaccine. And they’re looking at that more in the setting of prevention in high-risk patients or intercepting earlier cancers. So, for example, colon cancer, people with a genetic syndrome that predisposes them. Or in breast cancer, people with the BRCA1 or 2 mutations.
Meaning essentially it’s in their DNA, it’s in their family.
Already, yes. So they’re already at increased risk or people who have a precursor condition like they have polyps. Because you’re narrowing the population. And so they’re looking at could we develop vaccines based on proteins that are common across breast cancer or across colon cancer, or across all cancers that you could then use to prevent cancer?
So far, it hasn’t happened, but there are some promising early studies that show it’s a possibility. It’s still years away. And it’s hard science and it might fail, but it is where I think researchers are excited about where this might go, and also where it has the possibility to affect the most people.
Because that would be the Holy Grail to look at someone whose family heredity tells us that they’re likely to get breast cancer and give them a vaccine at some early point in their life that prevents that breast cancer from ever taking off. That would be amazing. And it sounds like we’re maybe a little closer to that now than we were before this melanoma vaccine, but I’m looking at you and wondering if that’s entirely something we can say.
I mean, I think that work has been going on. We are in general in a place where this field, both people who are looking at vaccines to treat disease as well as vaccines to prevent disease. Overall, the field has gotten to a place where that work is much more feasible because of those advancements we talked about.
And we have some evidence now that it works to prevent a recurrence, prevent cancer from coming back. The question is, can we move it up earlier? And instead of preventing it from coming back, can we prevent it from ever really forming and taking off in the first place?
And meeting the requirements of what we traditionally think of as a vaccine, preventing the thing from ever happening at all.
That’s the dream.
Nina, thank you very much.
Thanks so much for having me.
We’ll be right back.
Here’s what else you need to know today.
- archived recording (sean duffy)
-
Here’s what we believe happened yesterday. In at least one of our remote FAA locations, a contractor was doing routine maintenance to switch telecommunication lines from old copper wire, and they were bringing it over to fiber. That contractor —
Over the weekend, US officials gave their fullest account so far of what they believe caused the rare ground stop that brought air travel across the country to a halt on Friday night.
- archived recording (sean duffy)
-
Now, the work happening was due to the age of the copper wire that we were replacing. It was such an old wire that it was being discontinued.
Transportation Secretary Sean Duffy blamed work by a contractor to replace an outdated router. That work, Duffy said, caused circuits in the nation’s air traffic network, including its radar system, to become overloaded and hand disrupted.
- archived recording (sean duffy)
-
And when we see that, your safety is paramount, we shut down the airspace and we do it safely.
The ground stop highlighted the vulnerability of America’s aging air traffic control system, which Duffy said requires tens of billions of dollars in urgent upgrades. And —
- archived recording (chris van hollen)
-
I have a path to get there, no doubt about it.
In an interview on Sunday with CNN, Democratic Senator Chris Van Hollen of Maryland said his effort to unseat Chuck Schumer and become his party’s next majority leader in the US Senate is gaining support.
- archived recording (chris van hollen)
-
Senator Schumer’s team put out a list just the other day of people, they said, who are voting for Senator Schumer. I can tell you that a number of those people on that list have actually committed to voting for me, and the others are very open to the idea of change there.
Schumer claims he already has enough support to win the election, which is scheduled to be decided by secret ballot on December 1. But Van Hollen, who is positioning himself as a populist underdog, said that Schumer’s support is weaker than it appears.
Today’s episode was produced by Alex Stern and Chris Benderev, with help from Eric Krupke, and Carlos Prieto. It was edited by MJ Davis Lin, with help from Annie Minoff, contains music by Marion Lozano, Rowan Niemisto, and Dan Powell, and was engineered by Alyssa Moxley. Our theme music is by Wonderly.
That’s it for “The Daily.” I’m Michael Barbaro. See you tomorrow.
